依倍大剂量冲击疗法对化疗相关性贫血的疗效分析(1)
 |
| 第1页 |
参见附件(2331KB，3页)。
【摘要】 目的 观察依倍大剂量冲击疗法对化疗相关性贫血的疗效及不良反应。方法 将101例化疗后贫血患者随机分入试验组或对照组。试验组采用依倍大剂量冲击疗法,具体用法为第1天给予依倍 40 000 U,然后在第3、5、8、10、12、15、17、19天给予依倍10 000 U,每12 h1次,依倍总剂量为200 000 U。对照组采用依倍常规剂量法,具体为依倍40 000 U,皮下注射,每周1次,连续6次,依倍总剂量为240 000 U。所有患者均观察6周,每2周进行1次疗效评价。结果 试验组治疗2周后血红蛋白明显升高,对照组4周后血红蛋白明显升高;试验组的4、6周血红蛋白值均高于对照组(P<0.05);试验组的2、4、6周有效率分别为41.2%、60.8%和84.3%,高于对照组的17.0%、29.8%和51.1%(P<0.01);在提高患者生活质量方面,试验组也优于对照组(P<0.05)。两组输血需求率及不良反应发生率无明显差异(P>0.05)。结论 依倍大剂量冲击疗法对化疗相关性贫血的疗效优于常规剂量法,不良反应无明显增加。
【关键词】依倍;化学治疗;贫血
The impact of high-dose erythropoietin therapy for chemotherapy-relatedanemia
SUN Yan-wei,ZHANG Ai-li,CHI Yu-hua,et al.Department of medical oncology,Rizhao people’s hospital,Shandong ,Rizhao 276800,China
【Abstract】 Objective To observe the impact and adverse reactions of high-dose erythropoietin therapy for chemotherapy-related anemia.Methods 101 cases of anemia after chemotherapy were randomly divided into test group or control group.Test group were treated with high-dose erythropoietin therapy,the specific use for the first 1 day for rhEPO 40 000 U,and in the 3th,5th,8th,10th,12th,15th,17th,19th day given rhEPO10 000 U,every 12 hours one time,rhEPO total dose of 200 000 U.The control group were treated with conventional doses of erythropoietin law,in particular for Erythropoietin 40 000 U,subcutaneously,one time per week for 6 times,rhEPO total dose of 240 000 U.All patients were observed in 6 weeks,every 2 weeks a second efficacy evaluation.Results The test group after 2 weeks of treatment hemoglobin was significantly higher in the control group after 4 weeks was significantly higher hemoglobin;experimental group of 4,6 weeks hemoglobin values were higher(P<0.05);trial group of 2,4,6 weeks effective rate was 41.2%,60.8%and 84.3%,higher than 17.0%,29.8%and 51.1%(P<0.01);in improving the quality of life of patients,the test group is better than the control group(P<0.05).Two groups the rate of blood transfusion requirements and adverse reaction rates no significant difference(P>0 ......
您现在查看是摘要介绍页，详见PDF附件(2331KB，3页)。